Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723983 · ClinicalTrials.gov registry record · Phase 1
Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period
A Phase 1 study, sponsored by NuPathe.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00723983 is a Phase 1 study that has completed, run by NuPathe. The registered enrollment target is 23 participants.
The verdict
NCT00723983, a Phase 1 study, has completed, sponsored by NuPathe.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.
Interventions
- DRUG Sumatriptan succinate
- DRUG NP101 Study Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723983
The ClinicalTrials.gov registry entry for NCT00723983 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NuPathe, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sumatriptan succinate is the first listed.
NCT00723983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00723983 about?
NCT00723983 is a clinical study titled "Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period". To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.
What is the current status of trial NCT00723983?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2008-11. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00723983?
The interventions under investigation include: Sumatriptan succinate (DRUG), NP101 Study Patch (DRUG).
Who is sponsoring clinical trial NCT00723983?
This trial is sponsored by NuPathe, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.